ICCC vs NEOG

For growth investors, ImmuCell Corporation (ICCC) is the stronger pick with 51.

6% revenue growth year-over-year, versus -3. 2% for Neogen Corporation (NEOG). Analysts rate Neogen Corporation (NEOG) a "Hold" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ImmuCell Corporation (ICCC) delivered a total return of -15.

3%, compared to -80. 6% for Neogen Corporation (NEOG). Over 10 years, the gap is even starker: ICCC returned +16. 2% versus NEOG's -50. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ImmuCell Corporation (ICCC) is the lower-risk stock at 0.

38β versus Neogen Corporation's 1. 69β — meaning NEOG is approximately 349% more volatile than ICCC relative to the S&P 500. On balance sheet safety, Neogen Corporation (NEOG) carries a lower debt/equity ratio of 44% versus 55% for ImmuCell Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ImmuCell Corporation (ICCC) is pulling ahead at 51.

6% versus -3. 2% for Neogen Corporation (NEOG). On earnings-per-share growth, the picture is similar: ImmuCell Corporation grew EPS 65. 3% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, NEOG leads at 19. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ImmuCell Corporation (ICCC) is the more profitable company, earning -8.

1% net margin versus -122. 1% for Neogen Corporation — meaning it keeps -8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NEOG leads at 1. 1% versus -6. 2% for ICCC. At the gross margin level — before operating expenses — NEOG leads at 47. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ImmuCell Corporation (ICCC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

38)). Neogen Corporation (NEOG) carries a higher beta of 1. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ICCC: +16. 2%, NEOG: -50. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ICCC is a small-cap high-growth stock; NEOG is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.